Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Zelira Therapeutics Limited
  6. News
  7. All News
    ZLD   AU000000ZLD1

ZELIRA THERAPEUTICS LIMITED

(ZLD)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about ZELIRA THERAPEUTICS LIMITED
01/18ZELIRA THERAPEUTICS : Application for quotation of securities - ZLD
PU
01/12Argenica Therapeutics Appoints New Head of Clinical Development
MT
01/12ZELIRA THERAPEUTICS : 2021 Annual General Meeting Presentation
PU
01/11Zelira Therapeutics Secures R&D Tax Rebate; Shares Rise 3%
MT
01/10Zelira Therapeutics Receives Partial Payment for Technology License Fee
MT
2021Med Journal Publishes Results of Zelira Therapeutics' Medicinal Cannabis Product for Ch..
MT
2021Zelira Therapeutics Expands to New Zealand with New Distribution Deal
MT
2021Zelira Therapeutics Limited Expands into New Zealand Via Exclusive Distribution Agreeme..
CI
2021Zelira Therapeutics Secures Ethics Approval for Phase 2 Trial of Chronic Pain Drug; Sha..
MT
2021ZLD Supports Levins Chronic Pain Trial Ethics Approval
CI
2021ZELIRA THERAPEUTICS : Notification regarding unquoted securities - ZLD
PU
2021Zelira Therapeutics Develops Cannabinoid Distillate Tech; Enters Licensing Deal with DR..
MT
2021ZELIRA THERAPEUTICS : Jumps 15% Following $5 Million Investment from US Family Office Fund
MT
2021ZELIRA THERAPEUTICS : Subsidiary Launches Acne Treatment Product Line in US; Shares Soar 1..
MT
2021Zelira Therapeutics Limited Launches RAF FIVE Acne Treatment Products
CI
2021Zelira Therapeutics Seals Germany Distribution Deal for Cannabis Medication for Insomni..
MT
2021Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2..
CI
2021ZELIRA THERAPEUTICS : Institutional Review Board Approves Zelira Therapeutics' Observation..
MT
2021Zelira Therapeutics Ltd Obtains IRB Approval for US Observational Clinical Pain Trial
CI
2021Zelira Therapeutics Ltd. Announces Clinical Trial Results of Zelira's Zenivol Published..
CI
2021Zelira Therapeutics Limited Researchers Develops New Technology to Improves Delivery of..
CI
2021Zelira Therapeutics, Health House International Enter Five-Year Distribution Deal for C..
MT
2021Health House International Limited Signs 5 Year Exclusive Distribution Agreement with Z..
CI
2021ZELIRA THERAPEUTICS : Strikes Licensing, Management Deal for Pain Treatment Trial of Canna..
MT
2021Zelira Therapeutics Licenses Its ZTL-106 Proprietary Cannabinoid Formulation to Levin H..
CI
2021ZELIRA THERAPEUTICS : Launches HOPE Range of Products in Washington DC
MT
2021Zelira Therapeutics Limited Announces Partnership with Alternative Solutions Llc
CI
2021Zelira Therapeutics Ltd. Announces Change of Company Address
CI
2021ZELIRA THERAPEUTICS : Posts Record Revenue Growth in Fiscal Third Quarter
MT
2021Zelira Therapeutics Ltd Announces Sales Results for the Third Quarter Ended March 2021
CI
2021Zelira Therapeutics Limited Announces Executive Changes
CI
2021Richard Hopkins to Step-Down as Chief Executive Officer of Zelira Therapeutics Limited
CI
2020Zelira Therapeutics Ltd Announces Clarification Regarding HOPE Distribution to Washingt..
CI
2020ZELIRA THERAPEUTICS : Signs Distribution Partnership for Hope Products in Washington DC; S..
MT
2020Zelira Therapeutics Ltd Announces to Enter into A Binding Licensing Agreement with Alte..
CI
2020ZELIRA THERAPEUTICS : Rises 9% on Distribution Agreement for CBD Toothpaste in US
MT
2020ZLD Partners with SprinJene to Launch CBD Toothpaste in US
CI
2020Zelira Therapeutics Seals Partnership with Emyria for Autism Observational Trial
MT
2020Zelira Therapeutics Ltd Announces Its Proprietary Cannabinoid Medicines HOPE 1TM and HO..
CI
2020Zelira Therapeutics Ltd. Announces Zenivol Launches in Australia After TGA Approves Rel..
CI
2020Zelira Therapeutics Limited Forms Subsidiary to Launch Oral Care Products in USA
CI
2020Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2..
CI
2020Zelira Therapeutics Ltd Announces the Launch of HOPETM 1 & 2 for Autism Sufferers in th..
CI
2020Zelira Therapeutics Limited announced that it has received AUD 8.749378 million in fund..
CI
2020Zelira Therapeutics Limited announced that it expects to receive AUD 8.749378 million i..
CI
2020Zelira Therapeutics Limited Enters into A Commercial Agreement to Develop Products Targ..
CI
2020Zelira Therapeutics Limited Receives Final Clinical Report for Its Phase 1 Dose Escalat..
CI
2020Zelira Therapeutics Ltd Enters into Non-Binding Heads of Agreement with Kevin Growing P..
CI
2020Zelira Therapeutics Ltd Receives Final Clinical Report for its Phase 1a/2b Medicinal Ca..
CI
2020Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 3..
CI
2020Zelira Therapeutics Limited Announces That Its Phase 1 Dose Escalation Trial in Patient..
CI
2020Zelira Therapeutics Limited Meets Primary Endpoints for Phase (1b/2a) Medicinal Cannabi..
CI
2020Zelira Therapeutics Limited announced that it expects to receive AUD 4.5885 million in ..
CI
2020Zelira Therapeutics Limited to Collaborate with the Parkinsons Foundation
CI
2019Zelira Therapeutics Limited Announces to Advise the Last Patient Has Completed Dosing i..
CI
2019Zelda Therapeutics Ltd. has Changed its Name to Zelira Therapeutics Ltd
CI
2019Zelira Therapeutics Ltd Expands HOPE« Distribution in the U.S.A
CI
2019Zelda Therapeutics Limited completed the acquisition of Ilera Therapeutics LLC.
CI
2019Zelda Therapeutics Limited Announces Board Changes
CI
2019ZELDA THERAPEUTICS : Investor Presentation - Non-deal Roadshow
PU
2019Zelda Therapeutics Ltd Signs Distribution Agreement with Health House Holdings Ltd
CI
2019Zelda Therapeutics Limited Updates on Global Launch Strategy for HOPE Range of Products
CI
2019Zelda Therapeutics Supplies Cannabis Formulations to the CARE NSW Clinical Trial for Sy..
CI
2019Zeldas Phase II Insomnia Clinical Trial Fully Enrolled
CI
2019Zelda Therapeutics Limited signed an agreement to acquire Ilera Therapeutics LLC.
CI
2019Zelda Therapeutics Limited Announces Board Resignations
CI
2019Zelda Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 20..
CI
2019Zelda Therapeutics Limited Announces Approval for Opioid Reduction Trial
CI
2019Zelda Therapeutics Ltd Enters into Binding Heads of Agreement with Ilera Healthcare, LL..
CI
2019Zelda Therapeutics Ltd Announces Collaboration Identifies Novel Cannabis Pathway for Tr..
CI
2019Zelda Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31..
CI
2019Zelda Therapeutics Limited Announces Transition of Harry Karelis to a Non-Executive Cha..
CI
2019Zelda Therapeutics Ltd Provides Operational Update for the Three-Month Period to 31 Dec..
CI
2018Zelda Therapeutics Ltd Enters into Feasibility and Option Agreement with SUDA Pharmaceu..
CI
2018Zelda Therapeutics Limited Partners with St Vincent's Hospital on Opioid Reduction Stud..
CI
1  2Next
Upcoming event on ZELIRA THERAPEUTICS LIMITED
02/23/22